Abstract Details
Maria DeGraba
PRESENTER |
No disclosure on file |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
Orla Hardiman, MD, FRCP, FAAN (Trinity Biomedical Sciences Institute) | Dr. Hardiman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Pharmaceuticals. Dr. Hardiman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cytokinetics . Dr. Hardiman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hardiman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Taylor and Francis. The institution of Dr. Hardiman has received research support from Science Foundation Ireland. The institution of Dr. Hardiman has received research support from HRB. |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
Thomas DeGraba, MD (Walter Reed Medical Center) | No disclosure on file |